Best Practices for Designing Informative Trials Including Women.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 885, doi. 10.1007/s11883-022-01064-0
- By:
- Publication type:
- Article
Works matching IS 15233804 AND DT 2022 AND VI 24 AND IP 11
Results: 6
1
2
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 861, doi. 10.1007/s11883-022-01063-1
- By:
- Publication type:
- Article
3
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 867, doi. 10.1007/s11883-022-01062-2
- By:
- Publication type:
- Article
4
Lp(a): a New Pathway to Target?
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 831, doi. 10.1007/s11883-022-01060-4
- By:
- Publication type:
- Article
5
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 839, doi. 10.1007/s11883-022-01059-x
- By:
- Publication type:
- Article
6
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice.
- Published in:
- Current Atherosclerosis Reports, 2022, v. 24, n. 11, p. 849, doi. 10.1007/s11883-022-01061-3
- By:
- Publication type:
- Article